[Role of adjuvant chemotherapy in the treatment of medulloblastoma in children].

Autor: Sachivko NV; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus., Konoplia NE, Petrovich SV, Sharak EV
Jazyk: ruština
Zdroj: Voprosy onkologii [Vopr Onkol] 2002; Vol. 48 (3), pp. 318-21.
Abstrakt: A retrospective review was carried out to evaluate the results of treatment (1989-1998) of 81 children, aged under 15, with primary medulloblastoma. Thirty-three patients received surgery and postoperative craniospinal radiotherapy; 48--adjuvant chemotherapy (VCR 1.5 mg/m2, i.v., 1 day; CCNU 75 mg/m2, per os, 1 day; cisplatin 80 mg/m2 or carboplatin 400 mg/m2, i.v., 1 day). Overall 9-year survival was 37 +/- 0.8%. This index in the adjuvant chemotherapy group was 59 +/- 0.8%, without chemotherapy--22 +/- 0.8%.
Databáze: MEDLINE